Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-45

When RAC had 1 complete response based on morphology, and a total of 3 out of 6 heavily pre treated patients bridged to transplant the headline of the announcement read,

"Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2"

I wouldn't even open that unless I was a shareholder. I've been known to scroll through the list of announcements daily looking for investment opportunities , and only open the ones that sound interesting, no doubt plenty of others do that as well.

Since that announcement on 27/05/22 Race has gone from $1.74 to $1.56 today.

When CU6 had 1 complete response the headline of the announcement read.

"Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq"

That would cause me to open that up and have a read as plenty of others must have as the share price has gone from $2.56 that day (30/04/24) to $6.56 today.

Hopefully I am comparing apples to apples as a lay investor, but complete response grabs my attention like nothing else.